Roche’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer
Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen approved for the treatment of unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer The Tecentriq combination improved overall survival and progression-free survival compared with sorafenib in people with unresectable HCC Approval by the China National Medical Products Administration brings... Read more